Pharmacological targeting of the ephrin receptor kinase signalling by GLPG1790 in vitro and in vivo reverts oncophenotype, induces myogenic differentiation and radiosensitizes embryonal rhabdomyosarcoma cells

BACKGROUND: EPH (erythropoietin-producing hepatocellular) receptors are clinically relevant targets in several malignancies. This report describes the effects of GLPG1790, a new potent pan-EPH inhibitor, in human embryonal rhabdomyosarcoma (ERMS) cell lines. METHODS: EPH-A2 and Ephrin-A1 mRNA expres...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Megiorni, Francesca, Gravina, Giovanni Luca, Camero, Simona, Ceccarelli, Simona, Del Fattore, Andrea, Desiderio, Vincenzo, Papaccio, Federica, McDowell, Heather P., Shukla, Rajeev, Pizzuti, Antonio, Beirinckx, Filip, Pujuguet, Philippe, Saniere, Laurent, der Aar, Ellen Van, Maggio, Roberto, De Felice, Francesca, Marchese, Cinzia, Dominici, Carlo, Tombolini, Vincenzo, Festuccia, Claudio, Marampon, Francesco
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2017
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6389084/
https://ncbi.nlm.nih.gov/pubmed/28985758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-017-0530-z
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars